1 / 4

Progressive Supranuclear Palsy Treatment Market, 2020 - 2027

Progressive supranuclear palsy (PSP) is a rare progressive condition that can cause problems with balance, movement, vision, speech, and swallowing. It is caused due to increasing numbers of brain cells getting damaged over time. Progressive supranuclear palsy (PSP) is also known as Steele-Richardson-Olszewski syndrome.

akshay925
Download Presentation

Progressive Supranuclear Palsy Treatment Market, 2020 - 2027

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Progressive Supranuclear Palsy Treatment Market, by Progressive Supranuclear Palsy Treatment Market, by Drug Type (Dopamine, Anticholinergic Agents, Tricyclic Drug Type (Dopamine, Anticholinergic Agents, Tricyclic Antidepressants, and Others), by Distribution Channel Antidepressants, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027 2027 Progressive supranuclear palsy (PSP) is a rare progressive condition that can cause problems with balance, movement, vision, speech, and swallowing. It is caused due to increasing numbers of brain cells getting damaged over time. Progressive supranuclear palsy (PSP) is also known as Steele-Richardson-Olszewski syndrome. Increasing incidence of progressive supranuclear palsy (PSP) is expected to boost the market. For instance, according to the Chicago Dizziness and Hearing, an article published in August 2020 reports that worldwide progressive supranuclear palsy is estimated to affect about 4-6.4/100,000 persons and the incident rate for new cases for ages 50-99 is estimated to be 5.3/100,000, and the crude incidence rate is 1.1/100,000. The global progressive supranuclear palsy treatment market is estimated to be valued at US$ 14.38 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020- 2027). The increasing product development and ongoing trials is expected to propel growth of the global The increasing product development and ongoing trials is expected to propel growth of the global progressive supranuclear palsy treatment market progressive supranuclear palsy treatment market Get PDF Brochure Of This Research Report @ Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/4277 https://www.coherentmarketinsights.com/insight/request-pdf/4277

  2. Major players in the market are focused on drug development for progressive supranuclear palsy treatment, which is expected to boost the market growth over the forecast period. For instance, in September 2020, Alzprotect announced the recruitment of the first five patients to be participated in its Phase IIa clinical trial with its drug candidate AZP2006 (EZEPROGIND) for progressive supranuclear palsy (PSP) treatment. PSP is an orphan disease and moreover the company received an orphan drug designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). However, failure of drug results in the clinical trial is expected to hinder the market growth over the forecast period. For instance, in July 2019, AbbVie, a biopharmaceutical company halted its Phase 2 trial of its anti-tau antibody ABBV-8E12 for progressive supranuclear palsy. The trial was stopped due to failure in futility analysis. Increasing incidence of progressive supranuclear palsy in North America is expected to boost the Increasing incidence of progressive supranuclear palsy in North America is expected to boost the market growth market growth North America is expected to hold dominant position in the global progressive supranuclear palsy treatment market, owing to increasing new cases of progressive supranuclear palsy in this region. For instance, according to the National Organization for Rare Disorders (NORD), an article published in 2017, report that progressive supranuclear palsy (PSP affects around 20,000 people in the U.S. each year. The study also states that PSP may affect as many as 5 in 100,000 people and males are affected more often than females. Global Progressive Supranuclear Palsy Treatment Market – Impact of Coronavirus (COVID-19) Global Progressive Supranuclear Palsy Treatment Market – Impact of Coronavirus (COVID-19) Pandemic Pandemic The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic. The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe. As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global progressive supranuclear palsy treatment drugs market during the forecast period.

  3. Research Methodology Research Methodology Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include: Primary Research (Trade Surveys and Experts Interviews) Primary Research (Trade Surveys and Experts Interviews) • Desk Research Desk Research • Proprietor Data Analytics Model Proprietor Data Analytics Model • In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings. Request Sample Copy of Research Report @ Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/4277 https://www.coherentmarketinsights.com/insight/request-sample/4277 Key Players Key Players Major players operating in the global progressive supranuclear palsy treatment market include AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc., UCB Biopharma, AlzProtect, Asceneuron Therapeutics, TauRx Pharmaceuticals, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

  4. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com Email: sales@coherentmarketinsights.com

More Related